📊 AMRN Key Takeaways
Is Amarin Corp. Plcuk (AMRN) a Good Investment?
Amarin is a cash-draining pharmaceutical company with declining revenue (-6.5% YoY) and severe operating losses (-25.1% margin), indicating fundamental business challenges in a highly competitive sector. While the fortress balance sheet ($131M cash, zero debt) provides survival runway, the absence of profitability trajectory or growth signals makes capital preservation the priority until commercial inflection becomes evident.
Amarin's fundamentals show a mixed but overall weak profile: revenue is declining, margins remain deeply negative, and the business is still unprofitable at both the operating and net income levels. The main offset is a very strong balance sheet with no long-term debt, ample liquidity, and slightly positive free cash flow, but that financial strength does not yet compensate for poor earnings quality and limited growth momentum.
Amarin Corp. Plcuk Key Strengths (AMRN)
- Fortress balance sheet with $131M cash and zero long-term debt providing financial flexibility
- Positive free cash flow ($6.1M) despite net losses shows management controls burn rate effectively
- Strong liquidity ratios (3.48x current, 2.46x quick) ensure no near-term solvency risk
- Strong liquidity with a 3.34x current ratio and $134.66M in cash
- Debt-free balance sheet provides flexibility and lowers financial risk
- Positive operating cash flow and free cash flow indicate the business is not currently cash-burning on a core basis
AMRN Stock Risks: Amarin Corp. Plcuk Investment Risks
- Revenue declining 6.5% YoY signaling product demand erosion or market share loss in competitive pharma landscape
- Deep operating losses (-$11.3M) and negative net margin (-23.3%) indicate business model is not self-sustaining
- Pharma sector requires continuous pipeline success; no evidence of blockbuster products or growth catalysts offsetting declines
- Revenue declined 6.5% year over year, signaling weak top-line momentum
- Operating and net margins remain negative, showing the business model is not yet sustainably profitable
- Returns on equity and assets are negative, indicating inefficient use of capital
Key Metrics to Watch
- Revenue stabilization and gross margin sustainability as indicators of product-market fit recovery
- Operating margin trajectory toward profitability; path to cash flow breakeven critical
- Cash runway calculation relative to burn rate; monitor when cash reserve drops below 18-month operating expense threshold
- Revenue growth trend and ability to stabilize or reaccelerate sales
- Operating margin and free cash flow consistency
Amarin Corp. Plcuk (AMRN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.48x current ratio provides a solid financial cushion.
AMRN Profit Margin, ROE & Profitability Analysis
AMRN vs Healthcare Sector: How Amarin Corp. Plcuk Compares
How Amarin Corp. Plcuk compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Amarin Corp. Plcuk Stock Overvalued? AMRN Valuation Analysis 2026
Based on fundamental analysis, Amarin Corp. Plcuk has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Amarin Corp. Plcuk Balance Sheet: AMRN Debt, Cash & Liquidity
AMRN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Amarin Corp. Plcuk's revenue has declined by 50% over the 5-year period, indicating business contraction. The most recent EPS of $-0.15 indicates the company is currently unprofitable.
AMRN Revenue Growth, EPS Growth & YoY Performance
AMRN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $42.0M | -$10.5M | $-0.03 |
| Q3 2025 | $42.3M | $1.5M | $-0.02 |
| Q2 2025 | $67.5M | $1.5M | $0.00 |
| Q1 2025 | $42.0M | -$10.0M | $-0.02 |
| Q3 2024 | $42.3M | $1.5M | $-0.05 |
| Q2 2024 | $67.5M | $1.5M | $0.00 |
| Q1 2024 | $56.5M | -$10.0M | $-0.02 |
| Q3 2023 | $66.1M | -$5.1M | $-0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Amarin Corp. Plcuk Dividends, Buybacks & Capital Allocation
AMRN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Amarin Corp. Plcuk (CIK: 0000897448)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AMRN
What is the AI rating for AMRN?
Amarin Corp. Plcuk (AMRN) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AMRN's key strengths?
Claude: Fortress balance sheet with $131M cash and zero long-term debt providing financial flexibility. Positive free cash flow ($6.1M) despite net losses shows management controls burn rate effectively. ChatGPT: Strong liquidity with a 3.34x current ratio and $134.66M in cash. Debt-free balance sheet provides flexibility and lowers financial risk.
What are the risks of investing in AMRN?
Claude: Revenue declining 6.5% YoY signaling product demand erosion or market share loss in competitive pharma landscape. Deep operating losses (-$11.3M) and negative net margin (-23.3%) indicate business model is not self-sustaining. ChatGPT: Revenue declined 6.5% year over year, signaling weak top-line momentum. Operating and net margins remain negative, showing the business model is not yet sustainably profitable.
What is AMRN's revenue and growth?
Amarin Corp. Plcuk reported revenue of $45.1M.
Does AMRN pay dividends?
Amarin Corp. Plcuk does not currently pay dividends.
Where can I find AMRN SEC filings?
Official SEC filings for Amarin Corp. Plcuk (CIK: 0000897448) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AMRN's EPS?
Amarin Corp. Plcuk has a diluted EPS of $-0.03.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is AMRN's fundamental grade?
Based on our AI fundamental analysis in June 2026, Amarin Corp. Plcuk has a C grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is AMRN stock overvalued or undervalued?
Valuation metrics for AMRN: ROE of -2.3% (sector avg: 15%), net margin of -23.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is AMRN's AI grade for 2026?
Our dual AI analysis gives Amarin Corp. Plcuk a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AMRN's free cash flow?
Amarin Corp. Plcuk's operating cash flow is $6.4M, with capital expenditures of $252.0K. FCF margin is 13.6%.
How does AMRN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -23.3% (avg: 12%), ROE -2.3% (avg: 15%), current ratio 3.48 (avg: 2).